上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话：021-61312973　　传真：021-55068248
网址：www.shyuanye.com
邮箱：shyysw@sina.com

产品名称：6,7-Dimethoxy-N-(4-phenoxyphenyl)-
产品别名：Src Inhibitor 1 ； Src Kinase Inhibitor 1; Src-I1

生物活性：

Description	Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor with IC_{50} values of 44 nM for Src and 88nM for Lck.
IC_{50} & Target	IC50: 44 nM (Src), 88 nM (Lck)[1]
In Vitro	Src-I1 is competitive with both ATP and peptide binding sites of the kinase. The IC_{50} values are 44 and 88 nM for Src and Lck, respectively[1]. Src-I1, is found to be a potent inhibitor of Src (IC_{50}=0.18 μM), but also inhibited other Src family members, such as Lck, Csk and Yes with similar potency to Src, and RIP2 (IC_{50}=0.026 μM) with even greater potency. In addition, it inhibited CHK2 with similar potency to Src, and Aurora B with slightly lower potency[2].

Solvent&Solubility

In Vitro:

DMSO : 9.09 mg/mL (24.34 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6781 mL	13.3905 mL	26.7809 mL
	5 mM	0.5356 mL	2.6781 mL	5.3562 mL
	10 mM	0.2678 mL	1.3390 mL	2.6781 mL

*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.请依序添加每种溶剂： 10% DMSO→ 90% (20% SBE-β-CD in saline)

Solubility: ≥ 0.91 mg/mL (2.44 mM); Clear solution

此方案可获得 ≥ 0.91 mg/mL (2.44 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 9.1 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

2.请依序添加每种溶剂： 10% DMSO →90% corn oil

Solubility: ≥ 0.91 mg/mL (2.44 mM); Clear solution

此方案可获得 ≥ 0.91 mg/mL (2.44 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 9.1 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。

References	[1]. Tian G, et al. Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines. Biochemistry. 2001 Jun 19;40(24):7084-91. [2]. Bain J, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
实验参考：	
Kinase Assay	Assays (25.5 μL volume) are carried out robotically at room temperature (21°C) and are linear with respect to time and enzyme concentration under the conditions used. Assays are performed for 30 min using Multidrop Micro reagent dispensers in a 96-well format. The concentration of magnesium acetate in the assays is 10 mM and [γ-^{33}P]ATP (800 c.p.m./pmol) is used at 5, 20 or 50 μM as indicated, in order to be at or below the $K_m$for ATP for each enzyme.The assays are initiated with MgATP, stopped by the addition of 5 μL of 0.5 M orthophosphoric acid and spotted on to P81 filter plates using a unifilter harvester. The IC_{50} values of inhibitors are determined after carrying out assays at ten different concentrations of each compound[2].
References	[1]. Tian G, et al. Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines. Biochemistry. 2001 Jun 19;40(24):7084-91. [2]. Bain J, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.